Elicio Therapeutics
$10.65
16
-$0.01-0.09% Thursday 20:00
Statistics
Day High
10.65
Day Low
10.24
52W High
14.93
52W Low
4.6
Volume
69,297
Avg. Volume
132,932
Mkt Cap
186.26M
P/E Ratio
-
Dividend Yield
-
Dividend
-
Upcoming
Earnings
20MayExpected
Expected EPS
-0.425
Actual EPS
N/A
Financials
-Profit Margin
Unprofitable0Revenue
-103.8MNet Income
Analyst Ratings
$17.00Average Price Target
The highest estimate is 17.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy 100%
Hold 0%
Sell 0%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow ELTX. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
Moderna
MRNA
Mkt Cap10.61B
BioNTech
BNTX
Mkt Cap24.99B
Novavax
NVAX
Mkt Cap1.36B
Gilead Sciences
GILD
Mkt Cap148.78B
AMGEN
AMGN
Mkt Cap160.66B
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Merck
MRK
Mkt Cap214.76B
Pfizer
PFE
Mkt Cap140.15B
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Novartis
NVS
Mkt Cap237.61B
About
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases. The company's lead product candidate is ELI-002, an AMP therapeutic vaccine for the treatment of KRAS-driven cancers. It is also developing ELI-004, an AMP-modified CpG adjuvant, a component of ELI-002; ELI-007, a lymph node targeted AMP-peptide vaccine for mutant BRAF-driven cancers; ELI-008, a multivalent lymph node targeted AMP-peptide vaccine for mutant TP53-expressing cancers; ELI-005, a vaccine candidate for the prevention of COVID-19; ELI-011 for the treatment of hematological cancers; and ELI-012, a mKRAS TCR T cell AMP-lifier designs to use in combination with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company is headquartered in Boston, Massachusetts.
Show more...
CEO
Mr. Robert T. Connelly
Employees
32
Country
US
ISIN
US28657F1030
Listings
0 Comments
Share your thoughts
FAQ
What is Elicio Therapeutics stock price today?▼
The current price of ELTX is $10.65 USD — it has decreased by -0.09% in the past 24 hours. Watch Elicio Therapeutics stock price performance more closely on the chart.
What is Elicio Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Elicio Therapeutics stocks are traded under the ticker ELTX.
Is Elicio Therapeutics stock price growing?▼
ELTX stock has risen by +2.01% compared to the previous week, the month change is a -12.42% fall, over the last year Elicio Therapeutics has showed a +77.2% increase.
What is Elicio Therapeutics market cap?▼
Today Elicio Therapeutics has the market capitalization of 186.26M
When is the next Elicio Therapeutics earnings date?▼
Elicio Therapeutics is going to release the next earnings report on May 20, 2026.
What were Elicio Therapeutics earnings last quarter?▼
ELTX earnings for the last quarter are -0.45 USD per share, whereas the estimation was -0.45 USD resulting in a -1.12% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Elicio Therapeutics revenue for the last year?▼
Elicio Therapeutics revenue for the last year amounts to 0 USD.
What is Elicio Therapeutics net income for the last year?▼
ELTX net income for the last year is -103.8M USD.
How many employees does Elicio Therapeutics have?▼
As of April 04, 2026, the company has 32 employees.
In which sector is Elicio Therapeutics located?▼
Elicio Therapeutics operates in the Health Care sector.
When did Elicio Therapeutics complete a stock split?▼
Elicio Therapeutics has not had any recent stock splits.
Where is Elicio Therapeutics headquartered?▼
Elicio Therapeutics is headquartered in Boston, US.